NDC 57894-503 – Darzalex Faspro
Daratumumab 1800 mg/15mL; Hyaluronidase (human Recombinant) 30000 U/15mL · Injection · Subcutaneous
Product NDC57894-503
Product details
- Brand name
- Darzalex Faspro
- Generic name
- Daratumumab and hyaluronidase-fihj (human recombinant)
- Labeler
- Janssen Biotech, Inc.
- Dosage form
- Injection
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761145
- Marketed since
- May 1, 2020
- Listing expires
- December 31, 2027
- Pharmacologic class
- CD38-directed Cytolytic Antibody; Endoglycosidase
Active ingredients
- Daratumumab 1800 mg/15mL
- Hyaluronidase (human Recombinant) 30000 U/15mL
Uses, dosage, side effects and warnings for Darzalex Faspro →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 57894-503-01 | 1 VIAL, SINGLE-DOSE in 1 BOX (57894-503-01) / 15 mL in 1 VIAL, SINGLE-DOSE | May 1, 2020 |